

Chinese biotech firm MGI Tech partners with French startup SeqOne for advanced genomic analysis

18 June 2024 | News

Validation of the SeqOne CE-IVD platform for germline and somatic analysis for use with MGI sequencers in routine diagnostics



China-based biotech company MGI Tech Co. has partnered with France-based startup SeqOne, a leading provider of AI-powered software to support genomic information-based decision-making to develop complete solutions for genomic science.

The collaboration between a pathology reference laboratory in Spain, Agilent Technologies, MGI and SeqOne aims at the technical validation of a routine workflow using Agilent Panels, Magnis lib prep automation, MGI DNBSEQ-G99 and SeqOne somaHRD, a clinically validated HRD signature solution, for 96 samples.

This all-in-one solution for molecular pathology laboratories will enable high-quality, efficient, and flexible HRD testing worldwide, including Genomic Instability Score and BRCA testing.

The MegaBOLT Bioinformatics Analysis Accelerator, a hardware acceleration system developed in-house by MGI and focused on MPS, is designed to ensure seamless integration and compatibility with SeqOne's AI-powered variant identification and analysis solution.

As part of the collaboration, MegaBOLT and the SeqOne platform will be combined to provide a versatile, cost-effective, intuitive and time-saving solution from sample to report, which is particularly attractive to high-throughput human genetics laboratories.

"By combining MGI's state-of-the-art sequencing technology with SeqOne's innovative genome analysis platform, we are able to deliver real insights and solutions for personalized medicine," explains DrYong Hou, General Manager, MGI Europe and Africa. "This collaboration underscores our commitment to advancing genomics research and giving clinicians the tools they need to deliver tailored treatments to their patients."